文献速递消化道肿瘤与早癌消化内镜

放疗改善pT1b食管鳞癌内镜黏膜下剥离术后淋巴血管侵犯患者的生存

Radiotherapy Improves Survival of Patients With Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer After Endoscopic Submucosal Dissection.
PubMed 文献 · Am J Gastroenterol · 2023-03-23

这项多中心横断面研究纳入中国11家医院2010年1月至2019年12月接受内镜黏膜下剥离术(ESD)的pT1bN0M0食管鳞癌患者161例,比较辅助放疗组(47例,29.2%)与单纯ESD组(114例,70.8%)的生存。总体两组总生存(OS)和无病生存(DFS)无显著差异,淋巴血管侵犯(LVI)是唯一预后因素;LVI+组辅助放疗显著改善生存,LVI-组未见改善。作者认为可根据LVI状态选择性辅助放疗。

要点

  • pT1b食管鳞癌ESD术后总体辅助放疗与单纯ESD的OS和DFS无显著差异。
  • LVI是唯一预后因素,LVI+组辅助放疗5年OS 91.7% vs 59.5%(P=0.050)。
  • LVI+组辅助放疗5年DFS 92.9% vs 42.6%(P=0.010),LVI-组未见改善。

核心结论

  • 辅助放疗可改善ESD术后pT1b食管鳞癌LVI+患者的生存,但对LVI-患者未见改善。
  • 基于LVI状态的选择性辅助放疗使生存率与一般人群相似。

研究设计与样本

  • 多中心横断面研究,纳入中国11家医院2010年1月至2019年12月接受ESD的pT1bN0M0食管鳞癌患者。
  • 共筛查774例,纳入161例;47例(29.2%)接受辅助放疗(RT组),114例(70.8%)仅接受ESD(非RT组)。

主要发现

  • RT组与非RT组的总生存(OS)和无病生存(DFS)无显著差异。
  • 淋巴血管侵犯(LVI)是唯一预后因素。
  • LVI+组辅助放疗5年OS为91.7% vs 59.5%(P=0.050),5年DFS为92.9% vs 42.6%(P=0.010)。
  • LVI-组辅助放疗5年OS为83.5% vs 93.9%(P=0.148),5年DFS为84.2% vs 84.7%(P=0.907)。
  • 标准化死亡比在LVI+接受放疗组为1.52(95%CI 0.04-8.45),LVI-未接受放疗组为0.55(95%CI 0.15-1.42)。

临床怎么用

  • 作者认为,pT1b食管鳞癌ESD术后可根据LVI状态选择性给予辅助放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adjuvant radiotherapy is recommended for pT1b esophageal squamous cell cancer (ESCC) after endoscopic submucosal dissection (ESD). However, it is unclear whether additional radiotherapy can improve patient survival. This study aimed to evaluate the efficacy of adjuvant radiotherapy after ESD for pT1b ESCC. METHODS: This was a multicenter, cross-sectional study involving 11 hospitals in China. Between January 2010 and December 2019, patients with T1bN0M0 ESCC treated with or without adjuvant radiotherapy after ESD were included. Survival between groups was compared. RESULTS: Overall, 774 patients were screened, and 161 patients were included. Forty-seven patients (29.2%) received adjuvant radiotherapy after ESD (RT group) and 114 (70.8%) underwent ESD alone (non-RT group). There were no significant differences in overall survival (OS) and disease-free survival (DFS) between the RT and non-RT groups. Lymphovascular invasion (LVI) was the only prognostic factor. In the LVI+ group, adjuvant radiotherapy significantly improved survival (5-year OS: 91.7% vs 59.5%, P = 0.050; 5-year DFS: 92.9% vs 42.6%, P = 0.010). In the LVI- group, adjuvant radiotherapy did not improve survival (5-year OS: 83.5% vs 93.9%, P = 0.148; 5-year DFS: 84.2% vs 84.7%, P = 0.907). The standardized mortality ratios were 1.52 (95% confidence interval 0.04-8.45) in the LVI+ group with radiotherapy and 0.55 (95% confidence interval 0.15-1.42) in the LVI- group without radiotherapy. DISCUSSION: Adjuvant radiotherapy could improve survival in pT1b ESCC with LVI+ other than LVI- after ESD. Selective adjuvant radiotherapy based on LVI status achieved survival rates similar to those of the general population.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yang X, Zhao L, Shi A, et al. Radiotherapy Improves Survival of Patients With Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer After Endoscopic Submucosal Dissection. Am J Gastroenterol. 2023. PMID: 36972240. doi:10.14309/ajg.0000000000002257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。